Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Albert Einstein College of Medicine
Hoosier Cancer Research Network
University Hospital Heidelberg
University Health Network, Toronto
Eastern Cooperative Oncology Group
Rutgers, The State University of New Jersey
Sumitomo Pharma America, Inc.
Cedars-Sinai Medical Center
Case Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
MacroGenics
Columbia University
Emory University
Medical College of Wisconsin
University of Nebraska
National Cancer Institute (NCI)
University of Washington
Medical College of Wisconsin
Novartis
Brigham and Women's Hospital
National Institutes of Health Clinical Center (CC)
University of Cincinnati
University of Pittsburgh
Massachusetts General Hospital
Assistance Publique Hopitaux De Marseille
Universitair Ziekenhuis Brussel
Incyte Corporation
Weill Medical College of Cornell University
LigaChem Biosciences, Inc.
Merck Sharp & Dohme LLC
UNICANCER
Institut Claudius Regaud
Sahlgrenska University Hospital
Federation Francophone de Cancerologie Digestive
Washington University School of Medicine
Icahn School of Medicine at Mount Sinai
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC
Cardiff University
Xiamen University
Jonsson Comprehensive Cancer Center
GERCOR - Multidisciplinary Oncology Cooperative Group
D'Or Institute for Research and Education
AIDS Malignancy Consortium
Instituto do Cancer do Estado de São Paulo
Sunnybrook Health Sciences Centre
Case Comprehensive Cancer Center